中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 7
Jul.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(7): 1734-1739

Role of lipopolysaccharide in the development and progression of liver cancer

DOI: 10.3969/j.issn.1001-5256.2023.07.032
  • 1.

    Department of Medical Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100039, China

  • 2.

    College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100089, China

Research funding:

Youth Program of National Natural Science Foundation of China (82003211)

More Information
  • Corresponding author: DUAN Xuezhang, duanxuezhang2006@163.com (ORCID: 0000-0002-1941-9317)
  • Received Date: 2022-10-11
  • Accepted Date: 2022-11-14
  • Published Date: 2023-07-20
    Abstract
  • Liver cancer is an important public health issue worldwide. With the improvements in high-throughput sequencing and gene editing techniques in recent years, studies have further revealed the biological mechanism of intestinal microflora in the development, progression, and metastasis of liver cancer via the gut-liver axis, and in particular, it has been found that lipopolysaccharide, a component of the outer membrane of gram-negative bacteria, can cause downstream immune cascade reactions. This article reviews the possible mechanism of action of intestinal microflora lipopolysaccharide in the development and progression of liver cancer from the aspects of the association between intestinal environmental changes and liver cancer, immunoregulation by lipopolysaccharide, and preclinical treatment.

     

    • FullText(HTML)
  • loading
    • References(44)
  • [1]
    SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
    [2]
    CULLIN N, AZEVEDO ANTUNES C, STRAUSSMAN R, et al. Microbiome and cancer[J]. Cancer Cell, 2021, 39(10): 1317-1341. DOI: 10.1016/j.ccell.2021.08.006.
    [3]
    BARTOLINI I, RISALITI M, TUCCI R, et al. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment[J]. World J Gastrointest Oncol, 2021, 13(11): 1616-1631. DOI: 10.4251/wjgo.v13.i11.1616.
    [4]
    RANF S. Immune sensing of lipopolysaccharide in plants and animals: Same but different[J]. PLoS Pathog, 2016, 12(6): e1005596. DOI: 10.1371/journal.ppat.1005596.
    [5]
    WENG MT, CHIU YT, WEI PY, et al. Microbiota and gastrointestinal cancer[J]. J Formos Med Assoc, 2019, 118(Suppl 1): S32-S41. DOI: 10.1016/j.jfma.2019.01.002.
    [6]
    SCHWABE RF, GRETEN TF. Gut microbiome in HCC-mechanisms, diagnosis and therapy[J]. J Hepatol, 2020, 72(2): 230-238. DOI: 10.1016/j.jhep.2019.08.016.
    [7]
    REN Z, LI A, JIANG J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma[J]. Gut, 2019, 68(6): 1014-1023. DOI: 10.1136/gutjnl-2017-315084.
    [8]
    ZHANG L, WU YN, CHEN T, et al. Relationship between intestinal microbial dysbiosis and primary liver cancer[J]. Hepatobiliary Pancreat Dis Int, 2019, 18(2): 149-157. DOI: 10.1016/j.hbpd.2019.01.002.
    [9]
    FERRERE G, WRZOSEK L, CAILLEUX F, et al. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice[J]. J Hepatol, 2017, 66(4): 806-815. DOI: 10.1016/j.jhep.2016.11.008.
    [10]
    KELLY CR, KHORUTS A, STALEY C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent clostridium difficile infection: A randomized trial[J]. Ann Intern Med, 2016, 165(9): 609-616. DOI: 10.7326/M16-0271.
    [11]
    MAO J, WANG D, LONG J, et al. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers[J]. J Immunother Cancer, 2021, 9(12): e003334. DOI: 10.1136/jitc-2021-003334.
    [12]
    MEIGHANI A, ALIMIRAH M, RAMESH M, et al. Fecal microbiota transplantation for clostridioides difficile infection in patients with chronic liver disease[J]. Int J Hepatol, 2020, 2020: 1874570. DOI: 10.1155/2020/1874570.
    [13]
    BUTEL MJ. Probiotics, gut microbiota and health[J]. Med Mal Infect, 2014, 44(1): 1-8. DOI: 10.1016/j.medmal.2013.10.002.
    [14]
    KHEDR O, EL-SONBATY SM, MOAWED F, et al. Lactobacillus acidophilus ATCC 4356 exopolysaccharides suppresses mediators of inflammation through the inhibition of TLR2/STAT-3/P38-MAPK pathway in DEN-induced hepatocarcinogenesis in rats[J]. Nutr Cancer, 2022, 74(3): 1037-1047. DOI: 10.1080/01635581.2021.1934490.
    [15]
    WANG H, REDDY ST, FOGELMAN AM. The role of gut-derived oxidized lipids and bacterial lipopolysaccharide in systemic inflammation and atherosclerosis[J]. Curr Opin Lipidol, 2022, 33(5): 277-282. DOI: 10.1097/MOL.0000000000000841.
    [16]
    SUN C, WANG Z, HU L, et al. Targets of statins intervention in LDL-C metabolism: Gut microbiota[J]. Front Cardiovasc Med, 2022, 9: 972603. DOI: 10.3389/fcvm.2022.972603.
    [17]
    FEMINÒ R, FEMINÒ G, CAVEZZI A, et al. PCSK9 inhibition, LDL and lipopolysaccharides: a complex and "dangerous" relationship[J]. Int Angiol, 2021, 40(3): 248-260. DOI: 10.23736/S0392-9590.21.04632-0.
    [18]
    ZHENG Z, WANG B. The gut-liver axis in health and disease: The role of gut microbiota-derived signals in liver injury and regeneration[J]. Front Immunol, 2021, 12: 775526. DOI: 10.3389/fimmu.2021.775526.
    [19]
    ZHOU Y, ZHENG T, CHEN H, et al. Microbial intervention as a novel target in treatment of non-alcoholic fatty liver disease progression[J]. Cell Physiol Biochem, 2018, 51(5): 2123-2135. DOI: 10.1159/000495830.
    [20]
    GAO Q, ZHU H, DONG L, et al. Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma[J]. Cell, 2019, 179(2): 561-577. e22. DOI: 10.1016/j.cell.2019.08.052.
    [21]
    GHOSH SS, WANG J, YANNIE PJ, et al. Intestinal barrier dysfunction, LPS translocation, and disease development[J]. J Endocr Soc, 2020, 4(2): bvz039. DOI: 10.1210/jendso/bvz039.
    [22]
    BENTALA H, VERWEIJ WR, HUIZINGA-VAN DER VLAG A, et al. Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide[J]. Shock, 2002, 18(6): 561-566. DOI: 10.1097/00024382-200212000-00013.
    [23]
    S C H R O M M A B , B R A N D E N B U R G K , L O P P N O W H , e t a l . T h e c h a r g e o f e n d o t o x i n m o l e c u l e s i n f l u e n c e s t h e i r c o n f o r m a t i o n a n d I L - 6 - i n d u c i n g c a p a c i t y [ J ] . J I m m u n o l , 1 9 9 8 , 1 6 1 ( 1 0 ) : 5 4 6 4 - 5 4 7 1 . D O I :
    [24]
    LI T, WAN B, HUANG J, et al. Comparison of gene expression in hepatocellular carcinoma, liver development, and liver regeneration[J]. Mol Genet Genomics, 2010, 283(5): 485-492. DOI: 10.1007/s00438-010-0530-y.
    [25]
    LUEDDE T, SCHWABE RF. NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2011, 8(2): 108-118. DOI: 10.1038/nrgastro.2010.213.
    [26]
    YU LX, YAN HX, LIU Q, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents[J]. Hepatology, 2010, 52(4): 1322-1333. DOI: 10.1002/hep.23845.
    [27]
    DAPITO DH, MENCIN A, GWAK GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J]. Cancer Cell, 2012, 21(4): 504-516. DOI: 10.1016/j.ccr.2012.02.007.
    [28]
    CARACENI P, VARGAS V, SOLÀ E, et al. The use of rifaximin in patients with cirrhosis[J]. Hepatology, 2021, 74(3): 1660-1673. DOI: 10.1002/hep.31708.
    [29]
    HAN X, LUO Z, WANG W, et al. Efficacy and safety of rifaximin versus placebo or other active drugs in critical ill patients with hepatic encephalopathy[J]. Front Pharmacol, 2021, 12: 696065. DOI: 10.3389/fphar.2021.696065.
    [30]
    MA C, HAN M, HEINRICH B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360(6391): eaan5913. DOI: 10.1126/science.aan5931.
    [31]
    PONZIANI FR, NICOLETTI A, GASBARRINI A, et al. Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2019, 11: 1758835919848184. DOI: 10.1177/1758835919848184.
    [32]
    JUNG IH, CHOI JH, CHUNG YY, et al. Predominant activation of JAK/STAT3 pathway by interleukin-6 is implicated in hepatocarcinogenesis[J]. Neoplasia, 2015, 17(7): 586-597. DOI: 10.1016/j.neo.2015.07.005.
    [33]
    TAUB R. Hepatoprotection via the IL-6/Stat3 pathway[J]. J Clin Invest, 2003, 112(7): 978-980. DOI: 10.1172/JCI19974.
    [34]
    YANG J, ZHANG JX, WANG H, et al. Hepatocellular carcinoma and macrophage interaction induced tumor immunosuppression via Treg requires TLR4 signaling[J]. World J Gastroenterol, 2012, 18(23): 2938-2947. DOI: 10.3748/wjg.v18.i23.2938.
    [35]
    ZENG L, O'CONNOR C, ZHANG J, et al. IL-10 promotes resistance to apoptosis and metastatic potential in lung tumor cell lines[J]. Cytokine, 2010, 49(3): 294-302. DOI: 10.1016/j.cyto.2009.11.015.
    [36]
    YU L, WANG L, YI H, et al. Beneficial effects of LRP6-CRISPR on prevention of alcohol-related liver injury surpassed fecal microbiota transplant in a rat model[J]. Gut Microbes, 2020, 11(4): 1015-1029. DOI: 10.1080/19490976.2020.1736457.
    [37]
    WANG T, YU Y, LIANG X, et al. Lipid a has significance for optimal growth of coxiella burnetii in macrophage-like THP-1 cells and to a lesser extent in axenic media and non-phagocytic cells[J]. Front Cell Infect Microbiol, 2018, 8: 192. DOI: 10.3389/fcimb.2018.00192.
    [38]
    SHA T, SUNAMOTO M, KITAZAKI T, et al. Therapeutic effects of TAK-242, a novel selective Toll-like receptor 4 signal transduction inhibitor, in mouse endotoxin shock model[J]. Eur J Pharmacol, 2007, 571(2-3): 231-239. DOI: 10.1016/j.ejphar.2007.06.027.
    [39]
    HORIOKA K, TANAKA H, ISOZAKI S, et al. Acute colchicine poisoning causes endotoxemia via the destruction of intestinal barrier function: The curative effect of endotoxin prevention in a murine model[J]. Dig Dis Sci, 2020, 65(1): 132-140. DOI: 10.1007/s10620-019-05729-w.
    [40]
    MITRA S, ANAND U, SANYAL R, et al. Neoechinulins: Molecular, cellular, and functional attributes as promising therapeutics against cancer and other human diseases[J]. Biomed Pharmacother, 2022, 145: 112378. DOI: 10.1016/j.biopha.2021.112378.
    [41]
    KIM KS, CUI X, LEE DS, et al. Anti-inflammatory effect of neoechinulin a from the marine fungus Eurotium sp. SF-5989 through the suppression of NF-кB and p38 MAPK Pathways in lipopolysaccharide-stimulated RAW264.7 macrophages[J]. Molecules, 2013, 18(11): 13245-13259. DOI: 10.3390/molecules181113245.
    [42]
    BUSATTO S, WALKER SA, GRAYSON W, et al. Lipoprotein-based drug delivery[J]. Adv Drug Deliv Rev, 2020, 159: 377-390. DOI: 10.1016/j.addr.2020.08.003.
    [43]
    LLOVET JM, KELLEY RK, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3.
    [44]
    YOSHIMOTO S, LOO TM, ATARASHI K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J]. Nature, 2013, 499(7456): 97-101. DOI: 10.1038/nature12347.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (311) PDF downloads(62) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return